• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, direct oral penicillin challenge in patients with a low-risk penicillin allergy was noninferior compared with standard-of-care skin testing followed by oral challenge. In patients with a low-risk history, direct oral penicillin challenge is a safe procedure to facilitate the removal of a penicillin allergy label.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04454229.PMID:37459086 | DOI:10.1001/jamainternmed.2023.2986
Source: Cancer Control - July 17, 2023 Category: Cancer & Oncology Authors: Ana Maria Copaescu Sara Vogrin Fiona James Kyra Y L Chua Morgan T Rose Joseph De Luca Jamie Waldron Andrew Awad Jack Godsell Elise Mitri Belinda Lambros Abby Douglas Rabea Youcef Khoudja Ghislaine A C Isabwe Genevieve Genest Michael Fein Cristine Radojici Source Type: research

Inpatient Direct Oral Penicillin Challenge – A Large Prospective Cohort Study
Penicillin allergies are associated with inferior patient and antimicrobial stewardship outcomes. The long-term implementation (3.5 years) of a whole-of-hospital program to assess the safety of inpatient delabeling by direct oral challenge for low-risk penicillin allergies in hospitalized inpatients at Austin Hospital and the Peter MacCallum Cancer Centre, Australia was described here.
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Kyra Chua, Sara Vogrin, Jamie Waldron, Elise Mitri, Rebecca Hall, Ana Maria Copaescu, Natasha Holmes, Jason Trubiano Source Type: research

BET Bromodomain Inhibitor iBET151 Impedes Human ILC2 Activation and Prevents Experimental Allergic Lung Inflammation
This study was supported by grants from GSK and the UK Medical Research Council (U105178805). Conflict of Interest Statement AM has grant funding from GSK and AstraZeneca/MedImmune. MB, DJ, AP, DT, and AvO are employees of GSK. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments We are grateful to the Ares staff, genotyping facility, and flow cytometry core for their technical assistance. We thank Jen Walker for advice on the manuscript. Supplementary Material The Supplem...
Source: Frontiers in Immunology - April 8, 2019 Category: Allergy & Immunology Source Type: research

Safety, Efficacy, and Clinical Impact of Penicillin Skin Testing in Immunocompromised Cancer Patients
ConclusionOur findings support PST use in immunocompromised hosts. The widespread use of PST in patients with cancer will allow for optimal use of antimicrobial therapy and stewardship, which are vital in a population at increased risk for infections.
Source: The Journal of Allergy and Clinical Immunology: In Practice - March 28, 2019 Category: Allergy & Immunology Source Type: research